Answer:
The total non controlling interest after the additional shares are issued is equal to $252,000.
Explanation:
Before the issue Sage co's had 20,000 shares with total equity value of $500,000. After the issue of 5000 shares worth $200,000, the total number of shares and equity would be -
Total number of shares = 25,000 ( 20,0000 + 5000 )
Total equity value = $700,000
Now Thyme inc owns 16,000 number of shares , which means that minority holds 9000 number of shares . Now the price per share would be =
TOTAL EQUITY / NUMBER OF SHARES
$700,000 / 25,000
= $28
NON CONTROLLING INTEREST = Minority shares x Price per shares
= 9000 x $28
= $252,000
I believe its B) the fourth and fifth
1. How much interest would you pay on a loan of $1,230 for 15 months at 15 percent APR if the interest is 18.75 per $100?
The chart probably refers to interest per $100 of loan. So, the interest for a $1,230 loan would be (1230/100) * 18.75 = 230.625 ~ 230.63
So, the answer will be B $230.63.
2. Sherri borrowed $3,200 at 13 percent APR for 18 months. If she must pay 19.5 per $100, what is the total interest?
3,200 / 100 = 32 ... x 19.5 = 624
Principal x int rate x time = 3200 x .13 x 1.5 yr = 624 interest
So, the answer will be the A $624.
3. What is the total amount that Sherri (in question number 2) will repay?
The correct answer will be the $3,824.
Answer:
$10,619.05
Explanation:
When sales is made at a tax rate of 5%, the entries to be posted in the proportion of the transaction amount
Dr Cash/ Accounts receivable 105%
Cr Sales revenue 100%
Cr Sales tax 5%
As such, if Sales Account totals $223,000 which includes both the sales revenue and the sales tax on the sales, it means that the accounts contains 105%, as such, the sales tax which is the amount owed the taxing agency
= 5/105 * $223,000
= $10,619.05
Answer:True
Explanation:
A significant risk device presents a potential for serious risk to the health, safety, or welfare of a subject.
It is classified as Significant risk device since it hopes that the new pacemaker will pose fewer risks to individuals when compared to the current commercially available product.
